[Federal Register Volume 59, Number 79 (Monday, April 25, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-9932]


[[Page Unknown]]

[Federal Register: April 25, 1994]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

 

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health; HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for U.S. companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
Licensing Specialist at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, suite 325, Rockville, 
Maryland 20852-3804 (telephone 301/496-7735; fax 301/402-0220). A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications. Issued patents may be obtained from 
the Commissioner of Patents, U.S. Patent and Trademark Office, 
Washington, DC 20231.

Attenuation of Ethyl Alcohol Intoxication With 2 Adrenoceptor 
Antagonists

Linnoila, M., Lister, R., Durcan, M. (NIAAA)
Serial No. 07/512,835 (DIV of 07/294,119)
U.S. Patent No. 5,109,007 issued 28 Apr 92
Licensing Specialist: Arthur J. Cohn

    A new method of treating ethyl alcohol intoxication through the use 
of antagonists for the 2 adrenoceptor has been discovered. 
Drugs based on these antagonists may have none of the potentially 
harmful sedative effects of the tranquilizers currently used. 
2 adrenoceptor agonists believed useful for this purpose 
include: atipamexole, idazoxan, imiloxan, yohimbine, Wyeth WY26703, 
Chinoin CH38083, Glaxo GR50360A, and Daiichi Seiyaku DG5128.

Rapid And Sensitive Test For Detecting Hepatitis A Virus

Robertson, B.H., Nainan, O.V., Brown, V.K., Margolis, H.S., Khanna, B. 
(CDC)
Filed 31 Jan 92
Serial No. 07/828,444 (CIP of 07/469,143)
Licensing Specialist: Girish C. Barua

    Diagnostic methods with improved sensitivity and specificity to 
hepatitis A virus (HAV) are needed. This novel assay can be used to 
test for general HAV infection as well as to differentiate between HAV 
genotype I, which is thought to be the most common HAV, and HAV 
genotype II, which differs genetically from HAV I (as well as HAV type 
III) by about 15%. Free HAV is removed from stool, environmental 
samples, and other materials by immunoselection of whole virus using 
high titer anti-HAV antibodies coated onto a solid phase; viral RNA is 
then denatured in the presence of primers that recognize all known HAV 
genotypes and that bind to viral RNA for reverse transcription into 
cDNA. PRC is used to amplify cDNA with Taq polymerase using either 
labeled or unlabeled primers, depending on whether information on virus 
type is desired. This novel method is faster and more specific than 
currently available assays.

Production of Isolated Proteinaceous Materials Using Recombinant Avipox 
Virus Vectors

Falkner, F.G., Dorner, F., Bodemer, W., Scheiflinger, F., Moss, B. 
(NIAID)
Filed 11 May 92
Serial No. 07/882,768 (CIP of 07/734,741, CIP of 07/339,738)
Licensing Specialist: Girish C. Barua

    This invention concerns the use of avipox viruses as vectors for 
the expression of foreign DNA in animal tissue culture. The viruses are 
constructed in the same convenient manner as recombinant vaccinia 
viruses, by recombination of a recombinant plasmid with wild type 
avipox virus. They have an advantage over vaccinia viruses in not being 
pathogenic for humans or mammals. The recombinant avipox viruses can, 
however, infect mammalian cell cultures as well as avian cell cultures.

Eukaryotic Expression Vector System

Giri, C.P., Ogawa, H., Harris, C.C. (NCI)
Filed 22 Mar 93
Serial No. 08/034,652
Licensing Specialist: Carl C. Floyd, Ph.D.

    The method presented here allows for the enrichment of full length 
cDNAs of genes selected by their phenotypes. This is achieved by 
providing a vector system capable of synthesizing sense and antisense 
RNAs in vitro to generate RNA probes for use in an RNA:RNA 
hybridization based subtraction method. It also provides such an 
RNA:RNA hybridization based subtraction method for enrichment of the 
rare cDNs of interest. This will allow the selection of rare human 
cDNAs, for example, where limited amounts of cells are available.

DNA Sequence Which Acts as a Chromatin Insulator Element To Protect 
Expressed Genes From Cis-Acting Regulatory Sequences

Chung, H.J. Felsenfeld, G. (NIDDK)
Filed 7 Apr 93
Serial No. 08/045,266
Licensing Specialist: Carl C. Floyd, Ph.D.

    Novel method of insulating functional DNA domains introduced into 
higher eukaryotic cells from the effects of the cell's cis-acting 
regulatory elements. The invention represents the first pure insulator 
to be demonstrated to function in human cells. The element promises to 
be a useful tool in gene therapy, gene transfer techniques, and studies 
involving gene regulation and other gene expression technologies.

Peptide Inhibitors of Protein Tyrosine Kinase--SH2 Interactions

Roller, P.P. Burke, T.R., Otaka, A., Nomizu, M. (NCI)
Filed 8 Jun 93
Serial No. 08/072,946
Licensing Specialist: Carl C. Floyd, Ph.D.

    The invention relates to synthetic peptides which are inhibitors of 
protein-protein interactions, specifically that interaction between a 
protein having a src homology domain (SH2 domain) and a protein having 
a phosphorylated tyrosine that is recognized by the SH2 domain. This 
type of interaction occurs during cellular signal transduction 
cascades. These cascades are central in the regulation of cellular 
proliferation and therefore their control is of importance to 
chemotherapeutic approaches to antitumor therapy.

Phosphonoalkyl Phenylalanine Compounds Suitably Protected for Use 
In Peptide Synthesis

Burke, T.R., Smyth, M.S., Lim, B.B. (NCI)
Filed 8 Jun 93
Serial No. 08/073,088
Licensing Specialist: Carl C. Floyd, Ph.D.

    Phosphono(difluromethyl)phenylalanine (F2Pmp) is a chemically and 
enzymatically stable mimetic of phosphotyrosine. The molecule is 
suitably protected for use in solid-phase peptide synthesis and could 
be the reagent of choice for synthesis of peptides containing stable 
phosphotyrosyl mimetics.

Three Highly Informative Microsatellite DNA Markers for Use In Human 
Individualization

Merril, C.R., Polymeropoulos, M.H. (NIMH)
Filed 9 Jun 93
Serial No. 08/074,275
Licensing Specialist: Carl C. Floyd, Ph.D.

    The present invention relates to genetic testing with polymorphic 
DNA markers. The repeat sequences of the markers provide a rapid and 
convenient high resolution process for distinguishing target nucleic 
acid segments on the basis of nucleotide differences according to human 
individualization wherein the nucleic acid segments differ in size. The 
invention has several applications in the areas of forensic screening, 
paternity and prenatal screening, as well as genetic mapping.

The First Immortalized Kaposi's Sarcoma Cell Line

Iskandar-Lunardi, Y.L., Gallo, R.C. (NCI)
Filed 20 Aug 93
Serial No. 08/110,175
Licensing Specialist: Carl C. Floyd, Ph.D.

    Kaposi's Sarcoma (KS) is the most common malignancy in patients 
with acquired immunodeficiency syndrome (AIDS) in the U.S. The present 
invention makes available cell lines that provide a means for testing 
anti-Kaposi's Sarcoma therapies in vitro, or a model animal system. The 
invention allows therapies to be tested and dosages to be optimized 
prior to testing in humans. The cell line also provides a means of 
developing novel antitumor therapies and facilitates studies of factors 
that influence the development and metastasis of malignancies.

The Cloning Of Perilipin Proteins

Londos, C., Greenberg, A.S., Kimmel, A.R., Egan, J.J. (NIDDK)
Filed 4 Oct 93
Serial No. 08/132,649
Licensing Specialist: Carl C. Floyd, Ph.D.

    Perilipins are found at the surface of lipid storage droplets of 
adipocytes. Little is known about the molecules on the surface of lipid 
droplets that may be involved in lipid metabolism and trafficking. The 
present invention provides isolated nucleic acid sequences which encode 
a family of perilipin proteins as well as isolated, purified perilipin 
proteins. These are useful as markers for differentiation of true 
adipocyte cells from non-adipocyte cells which, as a result of 
pathophysiological conditions, assume adipocyte characteristics.

    Dated: April 11, 1994.
Donald P. Christoferson,
Acting Director, Office of Technology Transfer.
[FR Doc. 94-9932 Filed 4-22-94; 8:45 am]
BILLING CODE 4140-01-M